To Correlate the Expression of KRAS and BRAF V600e with Histological Grades and Variants in Tissue Samples of Colorectal Carcinoma
DOI:
https://doi.org/10.37762/jgmds.10-2.399Keywords:
Colorectal cancer, KRAS & BRAF V600E Immunohistochemistry, Tumor Grades, Histological VariantAbstract
OBJECTIVES
This study aimed to correlate the expression of KRAS and BRAF V600E with histological grades and variants in tissue samples of colorectal carcinoma.
METHODOLOGY
In this cross-sectional study total of 51 cases of Colorectal cancer (CRC) were analyzed for immunohistochemical staining using KRAS and BRAF antibodies on representative tissue blocks. Clinical and pathological records were retrieved for the collection of data. The results of the immunohistochemical analysis were correlated with the recorded clinicopathological parameters.
RESULTS
Fifty-one cases of CRC were analyzed for immunoexpression of KRAS and BRAF V600E. The age of the patients ranged from 14 to 85 years, with a mean age of 60.96 years. Among the 51 cases, 37(72.5%) cases were males and 14(27.4%) were females. 37(72.5%) were localized to left side colon and 14(27.4%) were found in the right colon. For KRAS immunostaining, 41(80.3%) out of 51 cases showed overexpression, while the remaining 10(19.6%) cases revealed negative expression. In the case of BRAF V600E, positive expression was seen in 20(39.2%) cases, whereas 31(60.7%) cases showed negative expression of BRAFV600E. A significant association was seen between KRAS overexpression and histological variants, i.e. glandular carcinomas.
CONCLUSION
Over-expression of KRAS was observed in advanced tumors. The presence of BRAF V600E mutation in the present study signifies the importance of BRAF V600E inhibitors as a potential alternate therapeutic tool in EGFR inhibitors and chemotherapy-resistant tumors.
Downloads
Metrics
References
Li-Chang HH, Kirsch R, Conner J, Sari A, Pollett A, El-Zimaity H, Jain D, Celli R, Reid SL, Riddell RH, Pollett A. Colorectal Carcinoma. Atlas of Intestinal Pathology: Volume 1: Neoplastic Diseases of the Intestines. 2019:15-25
Zdravkovic N, Pavlovic M, Radosavljevic G, Jovanovic I, Arsenijevic A, Zdravkovic N, Maric V, Loncarevic S, Srzentic Z, Jovanovic I. Serum levels of immunosuppressive cytokines and tumor markers in metastatic colorectal carcinoma. Journal of BUON. 2017;22:1-8.
Liu SL, Cheung WY. Role of surveillance imaging and endoscopy in colorectal cancer follow-up: Quality over quantity?. World journal of gastroenterology. 2019 Jan 7;25(1):59
Hohenberger W. Colorectal cancer–heading to the future. Innovative Surgical Sciences. 2018 Mar 1;3(1):1-2
Nikolouzakis TK, Vassilopoulou L, Fragkiadaki P, Mariolis Sapsakos T, Papadakis GZ, Spandidos DA, Tsatsakis AM, Tsiaoussis J. Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients. Oncology reports. 2018 Jun 1;39(6):2455-72
Haley L, Tseng LH, Zheng G, Dudley J, Anderson DA, Azad NS, Gocke CD, Eshleman JR, Lin MT. Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. Modern Pathology. 2015 Oct;28(10):1390-9
Loupakis F, Moretto R, Aprile G, Muntoni M, Cremolini C, Iacono D, Casagrande M, Ferrari L, Salvatore L, Schirripa M, Rossini D. Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. British journal of cancer. 2016 Jan;114(1):30-6
Roma C, Rachiglio AM, Pasquale R, Fenizia F, Iannaccone A, Tatangelo F, Antinolfi G, Parrella P, Graziano P, Sabatino L, Colantuoni V. BRAF V600E mutation in metastatic colorectal cancer: methods of detection and correlation with clinical and pathologic features. Cancer biology & therapy. 2016 Aug 2;17(8):840-8
Tan C, Du X. KRAS mutation testing in metastatic colorectal cancer. World journal of gastroenterology: WJG. 2022 Oct 7;18(37):5171
Jasar D, Filipovski V, Kubelka-Sabit K. Clinicopathological and histomorphological association in K-ras mutated colorectal cancer. Virchows Archiv. 2022(481):1-364
Zlatian OM, Comănescu MV, Roşu AF, Roşu LU, Cruce M, Găman AE, Călina CD, Sfredel V. Histochemical and immunohistochemical evidence of tumor heterogeneity in colorectal cancer. Rom J Morphol Embryol. 2015 Jan 1;56(1):175-81
Wan XB, Wang AQ, Cao J, Dong ZC, Li N, Yang S, Sun MM, Li Z, Luo SX. Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer. World journal of gastroenterology. 2019 Feb 21;25(7):808
Kim JK, Seong CY, Bae IE, Yi JW, Yu HW, Kim SJ, Won JK, Chai YJ, Choi JY, Lee KE. Comparison of immunohistochemistry and direct sequencing methods for identification of the BRAF V600E mutation in papillary thyroid carcinoma. Annals of surgical oncology. 2018 Jun 1;25(6):1775-81
Xie MZ, Li JL, Cai ZM, Li KZ, Hu BL. Impact of primary colorectal Cancer location on the KRAS status and its prognostic value. BMC gastroenterology. 2019 Dec;19(1):46
Bisht S, Ahmad F, Sawaimoon S, Bhatia S, Das BR. Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma. Medical oncology. 2014 Sep 1;31(9):124
Hussain M, Waqas O, Hassan U, Loya A, Akhtar N, Mushtaq S, Yusuf MA, Syed AA. Right-sided and left-sided colon cancers are two distinct disease entities: an analysis of 200 cases in Pakistan. Asian Pac J Cancer Prev. 2016;17(5):2545-8
Lemos Garcia J, Rosa I, Saraiva S, Marques I, Fonseca R, Lage P, Francisco I, Silva P, Filipe B, Albuquerque C, Claro I. Routine Immunohistochemical Analysis of Mismatch Repair Proteins in Colorectal Cancer—A Prospective Analysis. Cancers. 2022 Jul 31;14(15):3730
Dvorak K, Higgins A, Palting J, Cohen M, Brunhoeber P. Immunohistochemistry with Anti-BRAF V600E (VE1) mouse monoclonal antibody is a sensitive method for detection of the BRAF V600E mutation in colon cancer: Evaluation of 120 cases with and without KRAS mutation and literature review. Pathology & Oncology Research. 2019 Jan 15;25(1):349-59
González-Colunga KJ, Lino-Silva LS, Salcedo-Hernández RA, Ruiz-García EB, Zepeda-Najar C. BRAF V600E Expression by Immunohistochemistry in Colon Cancer and Clinico-pathologic Features Associated with BRAF-Mutated Colonic Cancers in Mexican Patients. Journal of gastrointestinal cancer. 2019 Jan 8:1-6
Chen D, Huang JF, Liu K, Zhang LQ, Yang Z, Chuai ZR, Wang YX, Shi DC, Huang Q, Fu WL. BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PloS one. 2014;9(3)
Cao J, Zhu X, Sun Y, Li X, Yun C, Zhang W. The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2022 Aug;49(10):3470-81
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Hina Wasti, Sumayyah Shawana, Sehrish Shafique, Yumna Shahid, Kiran Saleem, Santosh Kumar Sidhwani
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
